- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06890338
Eine Studie zur Bewertung der Antitumoraktivität von intravenös (iv) infundiertem Carboplatin mit Mirvetuximab Soravtansin bei Teilnehmern mit neu diagnostiziertem Folatrezeptor alpha (FRα), das seröse Epithel-Eierstock-Ovithel-, Fallopische Röhren oder primäre Peritonealkrebs exprimiert.
Eine einarmige Phase-2
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC).
Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). This is a single arm study in adult participants with advanced-stage Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) III-IV FRα-expressing serous EOC. Around 140 participants will be enrolled in the study at approximately 80 sites in the United States.
Participants will receive intravenous infusion of MIRV in combination with carboplatin on day 1 of each cycle, every 21 days for up to 6 - 9 Cycles. The total study duration will be approximately 3 years .
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: ABBVIE CALL CENTER
- Telefonnummer: 844-663-3742
- E-Mail: abbvieclinicaltrials@abbvie.com
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294
- Rekrutierung
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793
-
Mobile, Alabama, Vereinigte Staaten, 36604
- Rekrutierung
- Usa Mitchell Cancer Institute /ID# 276022
-
-
California
-
Irvine, California, Vereinigte Staaten, 92618
- Rekrutierung
- Kaiser Permanente - Irvine /ID# 276924
-
Los Angeles, California, Vereinigte Staaten, 90095
- Rekrutierung
- UCLA - University of California Los Angeles Medical Center /ID# 274566
-
San Diego, California, Vereinigte Staaten, 92103
- Rekrutierung
- Scripps Md Anderson - Prebys Cancer Center /ID# 276891
-
San Francisco, California, Vereinigte Staaten, 94109
- Rekrutierung
- California Pacific Medical Center - Van Ness Campus /ID# 275329
-
Santa Barbara, California, Vereinigte Staaten, 93105
- Aktiv, nicht rekrutierend
- Ridley Tree Cancer Center /ID# 275219
-
-
Connecticut
-
Danbury, Connecticut, Vereinigte Staaten, 06810
- Rekrutierung
- Danbury Hospital, Western Connecticut Health Network /ID# 274783
-
New Haven, Connecticut, Vereinigte Staaten, 06510
- Rekrutierung
- Yale University School of Medicine /ID# 275794
-
Norwalk, Connecticut, Vereinigte Staaten, 06856
- Rekrutierung
- Norwalk Hospital /ID# 274561
-
-
Florida
-
Jupiter, Florida, Vereinigte Staaten, 33458
- Rekrutierung
- Jupiter Medical Center /ID# 276616
-
Miami Beach, Florida, Vereinigte Staaten, 33140
- Abgeschlossen
- Mount Sinai Medical Center /ID# 274868
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60607
- Rekrutierung
- Rush Md Anderson Cancer Center /ID# 274926
-
Chicago, Illinois, Vereinigte Staaten, 60637
- Rekrutierung
- University of Chicago Medical Center /ID# 274796
-
Peoria, Illinois, Vereinigte Staaten, 61637-0001
- Rekrutierung
- OSF St. Francis Medical Center /ID# 274752
-
Urbana, Illinois, Vereinigte Staaten, 61801
- Rekrutierung
- Carle Foundation Hospital /ID# 276470
-
-
Indiana
-
Fort Wayne, Indiana, Vereinigte Staaten, 46845
- Rekrutierung
- Parkview Research Center /ID# 274338
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Rekrutierung
- Indiana University Melvin and Bren Simon Cancer Center /ID# 275492
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40503
- Rekrutierung
- Baptist Health Lexington /ID# 275218
-
Louisville, Kentucky, Vereinigte Staaten, 40207
- Rekrutierung
- Norton Cancer Institute - St. Matthews /ID# 276173
-
-
Louisiana
-
Covington, Louisiana, Vereinigte Staaten, 70433
- Rekrutierung
- Women'S Cancer Care /ID# 276469
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Rekrutierung
- University Medical Center New Orleans /ID# 274755
-
Shreveport, Louisiana, Vereinigte Staaten, 71103
- Rekrutierung
- Willis-Knighton Medical Center /ID# 274310
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- Rekrutierung
- University of Maryland, Baltimore /ID# 275308
-
Silver Spring, Maryland, Vereinigte Staaten, 20910
- Rekrutierung
- Holy Cross Hospital /ID# 275872
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455-0341
- Rekrutierung
- University of Minnesota - Minneapolis /ID# 275718
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Rekrutierung
- Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780
-
-
Mississippi
-
Jackson, Mississippi, Vereinigte Staaten, 39216
- Rekrutierung
- University Of Mississippi Medical Center /ID# 276342
-
-
Missouri
-
Springfield, Missouri, Vereinigte Staaten, 65807
- Rekrutierung
- Cox Medical Center South /ID# 274826
-
St Louis, Missouri, Vereinigte Staaten, 63141
- Rekrutierung
- Mercy David C. Pratt Cancer Center /ID# 275655
-
-
Nevada
-
Reno, Nevada, Vereinigte Staaten, 89511
- Rekrutierung
- The Center Of Hope /ID# 274313
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Rekrutierung
- Dartmouth-Hitchcock Medical Center /ID# 274676
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Rekrutierung
- John Theurer Cancer Center /ID# 275756
-
New Brunswick, New Jersey, Vereinigte Staaten, 08901
- Rekrutierung
- Rutgers Cancer Institute of New Jersey /ID# 274358
-
Teaneck, New Jersey, Vereinigte Staaten, 07666
- Rekrutierung
- Holy Name Medical Center /ID# 276240
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87109
- Rekrutierung
- Optimum Clinical Research Group /ID# 274583
-
-
New York
-
Bay Shore, New York, Vereinigte Staaten, 11706
- Rekrutierung
- Imbert Cancer Center /ID# 275634
-
Greenlawn, New York, Vereinigte Staaten, 11740
- Rekrutierung
- Northwell Health Cancer Institute At Huntington /ID# 276814
-
Lake Success, New York, Vereinigte Staaten, 11042
- Rekrutierung
- Northwell Health Center for Advanced Medicine. /ID# 275641
-
New York, New York, Vereinigte Staaten, 10032
- Rekrutierung
- Columbia University Irving Medical Center /ID# 276156
-
Rego Park, New York, Vereinigte Staaten, 11374
- Rekrutierung
- Northwell Health Queens Cancer Center /ID# 274850
-
West Islip, New York, Vereinigte Staaten, 11795
- Rekrutierung
- Good Samaritan Hospital Medical Center /ID# 274938
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27514
- Rekrutierung
- University of North Carolina Medical Center /ID# 275307
-
Charlotte, North Carolina, Vereinigte Staaten, 28204
- Rekrutierung
- Atrium Health Levine Cancer Institute /ID# 274557
-
Greenville, North Carolina, Vereinigte Staaten, 27834
- Rekrutierung
- East Carolina University - Brody School of Medicine /ID# 275770
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Rekrutierung
- Atrium Health Wake Forest Baptist Medical Center /ID# 276952
-
-
North Dakota
-
Fargo, North Dakota, Vereinigte Staaten, 58102
- Rekrutierung
- Sanford Fargo Medical Center - Fargo /ID# 275489
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Rekrutierung
- Cleveland Clinic - Cleveland /ID# 276133
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Rekrutierung
- Cleveland Clinic - Cleveland /ID# 278273
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Rekrutierung
- Cleveland Clinic - Cleveland /ID# 278274
-
Cleveland, Ohio, Vereinigte Staaten, 44109
- Rekrutierung
- Metrohealth Medical Center - Cleveland /ID# 276664
-
Columbus, Ohio, Vereinigte Staaten, 43219
- Rekrutierung
- The Mark H Zangmeister Center /ID# 275106
-
Kettering, Ohio, Vereinigte Staaten, 45429
- Rekrutierung
- Kettering Medical Center /ID# 274365
-
-
Oregon
-
Eugene, Oregon, Vereinigte Staaten, 97401
- Rekrutierung
- Oncology Associates of Oregon, P.C. /ID# 275006
-
Tigard, Oregon, Vereinigte Staaten, 97223
- Rekrutierung
- Compass Oncology - West - Tigard /ID# 275101
-
Kontakt:
- Site Coordinator
- Telefonnummer: (971) 708-7600
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Vereinigte Staaten, 18015
- Rekrutierung
- St. Lukes University Hospital /ID# 274362
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
- Rekrutierung
- West Penn Hospital /ID# 276028
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02905
- Rekrutierung
- Women & Infants Hospital /ID# 274716
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57105
- Rekrutierung
- Avera Cancer Institute - Sioux Falls /ID# 276226
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57104
- Rekrutierung
- Sanford Cancer Center /ID# 274901
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78731
- Rekrutierung
- Texas Oncology - Austin Central /ID# 275046
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Rekrutierung
- Texas Oncology - Fort Worth Cancer Center /ID# 275043
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- Houston Methodist Hospital /ID# 274568
-
Kontakt:
- Site Coordinator
- Telefonnummer: 713.441.3250
-
San Antonio, Texas, Vereinigte Staaten, 78240
- Rekrutierung
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 275090
-
The Woodlands, Texas, Vereinigte Staaten, 77380
- Rekrutierung
- Texas Oncology - The Woodlands /ID# 275015
-
Tyler, Texas, Vereinigte Staaten, 75702
- Rekrutierung
- Texas Oncology - Northeast Texas /ID# 275057
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22903
- Rekrutierung
- UVA Health University Hospital /ID# 275309
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Rekrutierung
- Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 276456
-
Norfolk, Virginia, Vereinigte Staaten, 23502-2800
- Rekrutierung
- Virginia Oncology Associates- Norfolk (Brock) /ID# 275227
-
Roanoke, Virginia, Vereinigte Staaten, 24014
- Rekrutierung
- Carilion Roanoke Memorial Hospital /ID# 274684
-
-
Washington
-
Spokane, Washington, Vereinigte Staaten, 99204
- Rekrutierung
- Providence Sacred Heart Medical Center & Children'S Hospital /ID# 274585
-
-
West Virginia
-
Morgantown, West Virginia, Vereinigte Staaten, 26506
- Rekrutierung
- West Virginia University School of Medicine /ID# 274556
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
-
Be judged by the investigator and/or treating physician to be an appropriate candidate to receive neoadjuvant chemotherapy.
-
Diagnosis of biopsy-confirmed high-grade, serous epithelial ovarian, fallopian tube or primary peritoneal cancer.
-
Participant meets the following disease criteria:
- Stage III or IV disease by the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) staging system, and
- Folate Receptor Alpha (FRα) expression positivity as defined by immunohistochemical staining of >= 75% of viable tumor cells with moderate >= 2+ membrane staining by the Ventana Folate Receptor Alpha (VENTANA FOLR1) assay, FOLR1 Eligibility Testing - Ventana FOLR1 (FOLR1-2.1) RxDx - Commercial or Central, and
- Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria.
Exclusion Criteria:
-
Endometrioid, clear cell, mucinous, or sarcomatous tumor histology; mixed tumors containing any of the above histologies; or low-grade/borderline ovarian tumor.
-
Previous clinical diagnosis of noninfectious interstitial lung disease, including noninfectious pneumonitis.
-
Previously treated with anticancer therapy including chemotherapy, radiation therapy, immunotherapy, or biologic agent for current cancer, with the exception of one cycle of single agent carboplatin
-
Participants with the following ocular history and/or concurrent disorders:
- History of corneal transplantation;
- Undergoing active postoperative management for refractive surgery, cataract surgery, corneal cross-linking, or corneal complications of surgery;
- Confluent superficial punctate keratopathy (SPK) not expected to resolve to non-confluence or better within the screening window with standard of care (SOC) intervention;
- Active or chronic clinically significant (>= Grade 3) corneal dystrophy (e.g., Fuchs dystrophy);
- Active ocular conditions requiring ongoing treatment/monitoring, such as glaucoma, which is not adequately controlled with medication or surgery, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema or an ocular condition with high risk of retinal detachment;
- Monocular vision with visual acuity in the worse eye, worse than 20/200 or visual fields less than 20 degrees (i.e., functional blindness in at least one eye).
-
History of other malignancy within 3 years prior to signing study consent. -- Note: Participants with tumors with a negligible risk for metastasis or death (e.g., adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Carboplatin + Mirvetuximab Soravtansine
Participants will receive carboplatin in combination with mirvetuximab soravtansine on Day 1 of a 21-day cycle per dose +/- Bevacizumab per investigator's discretion. |
Intravenous (IV) infusion
Andere Namen:
Intravenous (IV) infusion Intravenous (IV) infusion (per investigator's discretion) |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective Response (OR) by Independent Central Review (ICR)
Zeitfenster: Up to Approximately 3 years
|
OR is defined as the best overall response of radiographic complete response (CR) or partial response (PR) as assessed by ICR using RECIST Version 1.1 criteria, prior to any subsequent anticancer therapy, including interval debulking surgery (IDS). |
Up to Approximately 3 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants with Adverse Events (AE)
Zeitfenster: Up to Approximately 3 years
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug. |
Up to Approximately 3 years
|
|
Percentage of Participants with AEs leading to study drug discontinuation or dose modification
Zeitfenster: Up to Approximately 3 years
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug. |
Up to Approximately 3 years
|
|
Objective Response (OR) by Investigator
Zeitfenster: Up to Approximately 3 years
|
OR is defined as the best overall response of radiographic CR or PR as assessed by investigator using RECIST Version 1.1 criteria, prior to any subsequent anticancer therapy, including IDS. |
Up to Approximately 3 years
|
|
Disease Control by ICR
Zeitfenster: Up to Approximately 3 years
|
Disease control defined as CR, PR, or stable disease (SD) as assessed by ICR per RECIST Version 1.1 prior to subsequent anticancer therapy including IDS. |
Up to Approximately 3 years
|
|
Disease control by Investigator
Zeitfenster: Up to Approximately 3 years
|
Disease control defined as CR, PR, or stable disease (SD) as assessed by investigator per RECIST Version 1.1 prior to subsequent anticancer therapy including IDS. |
Up to Approximately 3 years
|
|
Percentage of Participants With CA-125 Confirmed Response Per Gynecologic Cancer Intergroup (GCIG) Criteria
Zeitfenster: Up to Approximately 3 years
|
The GCIG CA-125 response was defined as at least 50% reduction in CA-125. |
Up to Approximately 3 years
|
|
Progression-Free Survival (PFS) by investigator
Zeitfenster: Up to Approximately 3 years
|
PFS by investigator, defined as the time from the date of C1D1 until PD per RECIST v1.1 as assessed by investigator or death from any cause, whichever occurs first. |
Up to Approximately 3 years
|
|
Percentage of Participants that Underwent Interval debulking surgery (IDS)
Zeitfenster: Up to Approximately 3 years
|
Percentage of participants that underwent IDS during the course of the study treatment |
Up to Approximately 3 years
|
|
Percentage of participants with complete tumor cytoreduction at IDS
Zeitfenster: Up to Approximately 3 years
|
Complete tumor cytoreduction is defined as the absence of macroscopically visible residual disease at the end of the surgery |
Up to Approximately 3 years
|
|
Percentage of participants with Incomplete Tumor Cytoreduction at IDS
Zeitfenster: Up to Approximately 3 years
|
Defined as macroscopically visible residual tumor (≤ 1 cm or > 1cm) at the end of surgery. |
Up to Approximately 3 years
|
|
Change from baseline in disease-related symptoms as measured by the NCCN-FACT Ovarian Symptom Index (NFOSI-18) disease symptom subscale - physical (DRS-P)
Zeitfenster: Up to Approximately 3 years
|
The NFOSI-18 provides a total score that sums all 18 items, plus 2 multi-item scales that assess physical disease-related symptoms (DRS-P; 9 items) and general function/well-being (F/WB; 3 items). |
Up to Approximately 3 years
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Erkrankungen des endokrinen Systems
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Neubildungen nach histologischem Typ
- Genitalerkrankungen, weiblich
- Neoplasmen der endokrinen Drüse
- Neubildungen, Drüsen und Epithelien
- Eierstockerkrankungen
- Adnexerkrankungen
- Genitale Neubildungen, weiblich
- Gonadenstörungen
- Karzinom
- Eileitererkrankungen
- Eierstocktumoren
- Karzinom, Eierstockepithel
- Eileiterneoplasmen
- Aminosäuren, Peptide und Proteine
- Proteine
- Organische Chemikalien
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Koordinationskomplexe
- Bevacizumab
- Carboplatin
- Mirvetuximab Soravtansin
Andere Studien-ID-Nummern
- M25-231
- GOG-3115 (Andere Kennung: GOG)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-Sharing-Zeitrahmen
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD-Sharing-Zugriffskriterien
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .